These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24830305)

  • 1. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients.
    Rasmussen H; Ebdrup BH; Oranje B; Pinborg LH; Knudsen GM; Glenthøj B
    Int J Neuropsychopharmacol; 2014 Nov; 17(11):1729-36. PubMed ID: 24830305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.
    Rasmussen H; Ebdrup BH; Erritzoe D; Aggernaes B; Oranje B; Kalbitzer J; Pinborg LH; Baaré WF; Svarer C; Lublin H; Knudsen GM; Glenthoj B
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):583-92. PubMed ID: 20614105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.
    Rasmussen H; Erritzoe D; Andersen R; Ebdrup BH; Aggernaes B; Oranje B; Kalbitzer J; Madsen J; Pinborg LH; Baaré W; Svarer C; Lublin H; Knudsen GM; Glenthoj B
    Arch Gen Psychiatry; 2010 Jan; 67(1):9-16. PubMed ID: 20048218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
    J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
    Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
    J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia.
    Brecher M; Leong RW; Stening G; Osterling-Koskinen L; Jones AM
    J Clin Psychiatry; 2007 Apr; 68(4):597-603. PubMed ID: 17474816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
    O'Donoghue B; Schäfer MR; Becker J; Papageorgiou K; Amminger GP
    Early Interv Psychiatry; 2014 Aug; 8(3):276-80. PubMed ID: 23968390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.
    Erritzoe D; Rasmussen H; Kristiansen KT; Frokjaer VG; Haugbol S; Pinborg L; Baaré W; Svarer C; Madsen J; Lublin H; Knudsen GM; Glenthoj BY
    Neuropsychopharmacology; 2008 Sep; 33(10):2435-41. PubMed ID: 18288096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.
    Nielsen MØ; Rostrup E; Wulff S; Glenthøj B; Ebdrup BH
    JAMA Psychiatry; 2016 Feb; 73(2):121-8. PubMed ID: 26747088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
    Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
    Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
    Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
    Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms.
    Ebdrup BH; Skimminge A; Rasmussen H; Aggernaes B; Oranje B; Lublin H; Baaré W; Glenthøj B
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):69-82. PubMed ID: 20701823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine.
    Aggernaes B; Glenthoj BY; Ebdrup BH; Rasmussen H; Lublin H; Oranje B
    Int J Neuropsychopharmacol; 2010 Nov; 13(10):1383-95. PubMed ID: 20633319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
    Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
    J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nizatidine for the treatment of patients with quetiapine-induced weight gain.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B; Kilic N
    Hum Psychopharmacol; 2004 Jan; 19(1):37-40. PubMed ID: 14716710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
    Zhang ZJ; Yao ZJ; Zhang XB; Chen JF; Sun J; Yao H; Hou G; Zhang XB
    Acta Pharmacol Sin; 2003 Mar; 24(3):235-40. PubMed ID: 12617772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
    Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.